Sort by
Refine Your Search
-
gather insights from stakeholders, identify data and knowledge gaps, and respond to medical inquiries in a clear and scientifically accurate manner to guide healthcare provider and payer decision making
-
. For more information, visit www.takeda.com . Responsibilities Takeda Pharmaceutical Company is committed to striving towards better health for people and a brighter future for the world through
-
scientific and strategic assistance to safety product leads to support Alnylam products · Participate in the collection, interpretation, and presentation of safety data in internal forums · Support
-
. Through hands-on experience, fellows will work with various cross-functional teams to learn the role of Medical Affairs, develop skills in the analysis, interpretation, and communication of clinical data
-
of their choice, with options including Scientific Communications, Medical Information, Field Medical, or Medical Operations for the second year. Medical Affairs Fellowship Objectives: Develop in-depth knowledge
-
Communications, Medical Information, Field Medical, or Medical Operations for the second year. Medical Affairs Fellowship Objectives: · Develop in-depth knowledge of Intellia’s CRISPR gene editing technology
-
on the medical plan. US Medical directors play a key role in informing global product development and data generation strategies with perspective of US Region. The team also provides disease and product education
-
dissemination of data through strong stakeholder engagement, enabling scientific exchange, with the ultimate goal of improving the care of patients. Fellows can expect to drive Global Scientific Communication
-
from U.S. PhD degree candidates Additional Information Applicants should submit the following application materials by the priority deadline of October 31, 2025: 1. Curriculum vitae (CV), uploaded 2
-
Company Core Data Sheet (CCDS), US Package Insert (USPI), Summary of Product Characteristics (SmPC), and Structured Product Labeling (SPL). Support development of regulatory labeling strategy and the